Literature DB >> 20928961

Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.

John M Flack1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20928961      PMCID： PMC8673391          DOI： 10.1111/j.1751-7176.2010.00351.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  5 in total

1.  A study of the effects of lisinopril when used in addition to atenolol.

Authors:  K Soininen; L Gerlin-Piira; J Suihkonen; T Kyllönen; R Parviainen; E Kyllönen; K Hämäläinen; R Lonka; T Tikkanen; R Selonen
Journal:  J Hum Hypertens       Date:  1992-08       Impact factor: 3.012

2.  Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial.

Authors:  Gregg C Fonarow; Prakash Deedwania; Vivian Fonseca; Richard W Nesto; Karol Watson; Elizabeth Tarka; Mary Ann Lukas; Anuradha Madan; Mayadah Shabbout
Journal:  J Am Soc Hypertens       Date:  2009-03-29

3.  Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.

Authors:  Robert A Phillips; Vivian Fonseca; Richard E Katholi; Janet B McGill; Franz H Messerli; David S H Bell; Philip Raskin; Jackson T Wright; Malini Iyengar; Karen M Anderson; Mary Ann Lukas; George L Bakris
Journal:  J Cardiometab Syndr       Date:  2008

4.  Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.

Authors:  George L Bakris; Malini Iyengar; Mary Ann Lukas; Paul Ordronneau; Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-07-08       Impact factor: 3.738

5.  Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.

Authors:  Jackson T Wright; George L Bakris; David S H Bell; Vivian Fonseca; Richard E Katholi; Janet B McGill; Franz H Messerli; Robert A Phillips; Philip Raskin; Fred K Holdbrook; Mary Ann Lukas; Malini Iyengar
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.